loading page

Trial of Labour after Caesarean Section in Sub-Saharan Africa: A systematic review and meta-analysis
  • +5
  • Adeline Boatin,
  • Deen Garba,
  • Michala Sawyer,
  • Kaitlyn James,
  • Joseph Ngonzi,
  • Henry Lugobe,
  • Blair Wylie,
  • Kwame Adu-Bonsaffoh
Adeline Boatin
Massachusetts General Hospital

Corresponding Author:[email protected]

Author Profile
Deen Garba
The University of North Carolina at Chapel Hill School of Medicine
Author Profile
Michala Sawyer
Planned Parenthood Federation of America
Author Profile
Kaitlyn James
Massachusetts General Hospital
Author Profile
Joseph Ngonzi
Mbarara University of Science and Technology
Author Profile
Henry Lugobe
Mbarara University of Science and Technology
Author Profile
Blair Wylie
Beth Israel Deaconess Medical Center
Author Profile
Kwame Adu-Bonsaffoh
University of Ghana Medical School
Author Profile

Abstract

Background: Intrapartum decision-making for women with a previous caesarean section (CS) is complex due to competing risks of trial of labour after cesarean (TOLAC) and elective repeat CS (ERCS). Objective: Determine rates of TOLAC and vaginal birth after cesarean (VBAC) in sub-Saharan Africa (SSA) and estimate rates of adverse events associated with TOLAC versus ERCS. Search Strategy: We searched PubMed, MEDLINE, CAB, EMBASE, and African-specific databases. Selection Criteria: We included studies with at least one previous CS conducted in SSA. Data Collection and Analysis: We extracted data on study design, planned and actual delivery mode, and maternal and perinatal outcomes. We calculated median TOLAC and VBAC rates pooled mean uterine rupture rate and compared uterine rupture rates and mortality between TOLAC and ERCS. Main Results: From 51 included studies, the median TOLAC and VBAC rates, weighted for sample size, were 75% (IQR: 40-100%) and 34% (IQR: 24-44%) , respectively; and the weighted mean uterine rupture rate was 1.3% (SD: 1.6%). The uterine rupture rate [1.2% vs 0.2%, OR 1.54 (95% CI 0.63-3.75)] and maternal mortality [0.3% vs <0.1%, OR 0.77 (95% CI 0.30-1.98)] did not differ significantly between TOLAC and ERCS groups, respectively, however perinatal mortality was higher for the TOLAC group (5% vs 1%, OR 3.3 ; 95% CI 1.5-6.9) Conclusions: We found high rates of TOLAC and moderate rates of VBAC across SSA, with a perinatal but no maternal benefit to ERCS compared to TOLAC. Further research is needed to understand delivery outcomes in this population of women.